Recruiting | Phase II
Testing the Addition of Ruxolitinib to Usual Chemotherapy Before and After Surgery in Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer-Phase II Portion
To compare the effectiveness of the combination of Ruxolitinib with chemotherapy (Carboplatin and Paclitaxel) to the effectiveness of chemotherapy alone.
- Ruxolitinib, study agent (oral medication)
- Group 1: Treatment with carboplatin and paclitaxel for 3 cycles, then surgery to remove tumor tissue, then 3 more cycles of carboplatin and paclitaxel.
- Group 2: Treatment with carboplatin and paclitaxel for 3 cycles, then surgery to remove tumor tissue, then 3 more cycles of carboplatin and paclitaxel plus the study agent Ruxolitinib.
After completion of treatment you will be followed every three months for the first two years and then every six month for the next three years.
Key Participation Requirements:
19 years and older
Ovarian, Fallopian tube or peritoneal cancer which has spread beyond the pelvis
Cell type: Mullerian epithelial adenocarcinoma, high grade serous carcinoma, high grade endometrioid carcinoma, clear cell carcinoma or combination of these.
Patients must have untreated stage III or IV epithelial ovarian, primary peritoneal or fallopian tube cancer.
Patients must not have had surgery, chemotherapy or any other treatment for their cancer prior to enrollment in research study.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.